With the release of the WHO Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention in 2022, HIV prevention programs and implementing partners are preparing for rapid expansion of additional HIV pre-exposure prophylaxis (PrEP) methods. Experience from the scale-up of previous HIV prevention programs demonstrates the advantages of ready-made provider capacity building resources, developed specifically to align with WHO guidance and recommendations. With funding from PEPFAR through USAID, the Reaching Impact, Saturation, and Epidemic Control (RISE) project developed a suite of provider training resources on use of long-acting cabotegravir (CAB-LA) for HIV prevention, for self-paced digital, in-person classroom and/or blended delivery. The “Provider Training Toolkit on use of CAB-LA for PrEP” is designed to help clinicians learn about and support provision of CAB-LA as an additional HIV prevention option for their clients and an orientation to the Toolkit will be provided.